Overview
Schizophrenia, psychosis, cognition, pharmacologic treatment of cognitive impairment, sport psychology, functional imaging (PET, fMRI), frontal cortex, motor functions.
Current Duke Appointments & Affiliations
Professor Emeritus in Psychiatry and Behavioral Sciences
·
2022 - Present
Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences,
Psychiatry & Behavioral Sciences
Faculty Network Member of the Duke Institute for Brain Sciences
·
2008 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Recent Scholarly Works
Exploratory anchor-based analyses to determine minimal clinically important differences for the Brief Assessment of Cognition in Schizophrenia and the Schizophrenia Cognition Rating Scale.
Journal article Schizophr Res · November 2026 BACKGROUND: The Brief Assessment of Cognition in Schizophrenia (BACS) and Schizophrenia Cognition Rating Scale (SCoRS) tests help to assess cognition in schizophrenia; however, anchor-based determinations of meaningful change are needed. This analysis deri ... Full text Link to item CiteA phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study.
Journal article Neuropsychopharmacology · October 2026 The phase 2 ERUDITE (NCT05182476) study evaluated the efficacy and safety of luvadaxistat, a selective ᴅ-amino acid oxidase inhibitor, for cognitive impairment associated with schizophrenia. ERUDITE was a randomized, double-blind, placebo-controlled, paral ... Full text Link to item CiteCorrigendum to "exploratory anchor-based analyses to determine minimal clinically important differences for the brief assessment of cognition in schizophrenia and the schizophrenia cognition rating scale" [Schizophr. Res. 2026 July 25. doi:10.1016/j.schres.2026.07.021. Epub ahead of print].
Journal article Schizophr Res · October 2026 Full text Link to item CiteRecent Grants
A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrom
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2017 - 2021Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2019Study to Evaulate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry.
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2013 - 2017View All Grants
Education
New York University ·
1990
Ph.D.